{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T04:50:33Z","timestamp":1782190233134,"version":"3.54.5"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Metabolic-dysfunction-associated steatotic liver disease (MASLD) and MASLD with increased alcohol intake (MetALD) are overlapping but distinct conditions that influence liver disease progression and mortality. This study sought to examine how differing metabolic, behavioral, and sociodemographic profiles influence mortality in MASLD and MetALD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adults aged 20\u201379 years without a history of cancer, cardiovascular disease, or viral hepatitis were selected from the Korean National Health and Nutrition Examination Surveys (2007\u20132015). Mortality data up to November 2023 were obtained from the National Death Registry. MASLD and MetALD were defined using the hepatic steatosis index, cardiometabolic risk factors (CMRFs), and alcohol consumption.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 7,783 participants, weighted to represent approximately 7.6 million Korean adults, were included, with a median follow-up duration of approximately 4 years. Both MASLD and MetALD were associated with increased all-cause mortality compared to controls, with a significant increase observed in MetALD (HR 2.085; 95% CI, 1.127\u20133.860;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.019). The absolute all-cause mortality rates were 2.33% in the MetALD group and 1.05% in controls. Cancer-related mortality was significantly elevated in both MASLD (HR 2.610; 95% CI, 1.029\u20136.618;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.043) and MetALD (HR 3.355; 95% CI, 1.097\u201310.263;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.034). In MetALD, high alcohol consumption and current smoking were independent predictors of cancer-related and all-cause mortality. In MASLD, female sex and higher income were associated with reduced mortality. Cardiovascular mortality did not differ significantly between groups; however, in MASLD, each additional CMRF was associated with increased cardiovascular mortality (HR 1.838; 95% CI, 1.320\u20132.558;\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>While both MASLD and MetALD were associated with increased mortality, the contributing risk profiles differed. Alcohol-related behaviors predominated in MetALD, whereas metabolic and sociodemographic factors influenced outcomes in MASLD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1832416","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T04:35:13Z","timestamp":1782189313000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Divergent risk profiles for cause-specific mortality in MASLD and MetALD: a nationwide population-based study"],"prefix":"10.3389","volume":"13","author":[{"given":"Hyuk","family":"Kim","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital","place":["Bucheon, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong-Ju","family":"Yoo","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital","place":["Bucheon, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Digestive Disease Center, Institute for Digestive Research, Soonchunhyang University College of Medicine","place":["Seoul, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Young","family":"Jang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Digestive Disease Center, Institute for Digestive Research, Soonchunhyang University College of Medicine","place":["Seoul, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Ryu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Digestive Disease Center, Institute for Digestive Research, Soonchunhyang University College of Medicine","place":["Seoul, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soung Won","family":"Jeong","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Digestive Disease Center, Institute for Digestive Research, Soonchunhyang University College of Medicine","place":["Seoul, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Gyune","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital","place":["Bucheon, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Seok","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital","place":["Bucheon, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suyeon","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Soonchunhyang University Hospital","place":["Seoul, Republic of Korea"]},{"name":"Department of Applied Statistics, Chung-Ang University","place":["Seoul, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"197","DOI":"10.7570\/jomes23052","article-title":"Metabolic dysfunction-associated steatotic liver disease (MASLD): a state-of-the-art review.","volume":"32","author":"Chan","year":"2023","journal-title":"J Obes Metab Syndr"},{"key":"B2","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1136\/gutjnl-2023-331003","article-title":"Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease.","volume":"73","author":"Lee","year":"2024","journal-title":"Gut"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1097\/HEP.0000000000000664","article-title":"Prevalence, distribution, and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings.","volume":"79","author":"Lee","year":"2024","journal-title":"Hepatology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature.","volume":"79","author":"Rinella","year":"2023","journal-title":"J Hepatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"155789","DOI":"10.1016\/j.metabol.2024.155789","article-title":"Mortality in metabolic dysfunction-associated steatotic liver disease: a nationwide population-based cohort study.","volume":"152","author":"Han","year":"2024","journal-title":"Metabolism"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1111\/jgh.16592","article-title":"Prevalence, proportions of elevated liver enzyme levels, and long-term cardiometabolic mortality of patients with metabolic dysfunction-associated steatotic liver disease.","volume":"39","author":"Chen","year":"2024","journal-title":"J Gastroenterol Hepatol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1097\/HEP.0000000000000925","article-title":"MASLD\/MetALD and mortality in individuals with any cardio-metabolic risk factor: a population-based study with 26.7 years of follow-up.","volume":"81","author":"Kwak","year":"2025","journal-title":"Hepatology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/apt.18011","article-title":"Steatotic liver disease-associated all-cause\/cause-specific mortality in the United States.","volume":"60","author":"Kim","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1016\/j.jhep.2024.09.027","article-title":"Is MASLD a real culprit for all-cause mortality? A meta-analysis and preliminary pathophysiology exploration in the real world.","volume":"82","author":"Li","year":"2025","journal-title":"J Hepatol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.dld.2009.08.002","article-title":"Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease.","volume":"42","author":"Lee","year":"2010","journal-title":"Dig Liver Dis"},{"key":"B11","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.amjcard.2025.09.035","article-title":"Alcohol and cardiovascular disease.","volume":"259","author":"Gupta","year":"2026","journal-title":"Am J Cardiol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e019968","DOI":"10.1161\/JAHA.120.019968","article-title":"Sex differences in the associations of visceral adipose tissue and cardiometabolic and cardiovascular disease risk: the Framingham heart study.","volume":"10","author":"Kammerlander","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"B13","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1186\/s12889-023-15584-0","article-title":"Gender differences in metabolic syndrome and its components in southern china using a healthy lifestyle index: a cross-sectional study.","volume":"23","author":"Ye","year":"2023","journal-title":"BMC Public Health"},{"key":"B14","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1093\/aje\/kwae202","article-title":"Socioeconomic disparities in healthcare access and implications for all-cause mortality among US adults: a 2000-2019 record linkage study.","volume":"194","author":"Gulati","year":"2025","journal-title":"Am J Epidemiol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1186\/s12889-024-18676-7","article-title":"Does health literacy mediate the relationship between socioeconomic status and health related outcomes in the Belgian adult population?","volume":"24","author":"Berete","year":"2024","journal-title":"BMC Public Health"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1016\/j.numecd.2024.05.018","article-title":"Impacts of cardiometabolic risk factors and alcohol consumption on all-cause mortality among MASLD and its subgroups.","volume":"34","author":"Li","year":"2024","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e0214","DOI":"10.1097\/MD.0000000000010214","article-title":"Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD).","volume":"97","author":"Golabi","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"B18","doi-asserted-by":"publisher","first-page":"155642","DOI":"10.1016\/j.metabol.2023.155642","article-title":"Nonalcoholic fatty liver disease (NAFLD) and associated mortality in individuals with type 2 diabetes, pre-diabetes, metabolically unhealthy, and metabolically healthy individuals in the United States.","volume":"146","author":"Golabi","year":"2023","journal-title":"Metabolism"},{"key":"B19","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.3350\/cmh.2024.0431","article-title":"Epidemiology of metabolic dysfunction-associated steatotic liver disease.","volume":"31","author":"Younossi","year":"2025","journal-title":"Clin Mol Hepatol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"101388","DOI":"10.1016\/j.jhepr.2025.101388","article-title":"Impact of cardiometabolic risk factors on hepatic fibrosis and clinical outcomes in MASLD: A population-based multi-cohort study.","volume":"7","author":"Park","year":"2025","journal-title":"JHEP Rep"},{"key":"B21","doi-asserted-by":"publisher","first-page":"103965","DOI":"10.1016\/j.numecd.2025.103965","article-title":"Impact of cardiometabolic risk factors for metabolic dysfunction-associated steatotic liver disease on mortality.","volume":"35","author":"Kim","year":"2025","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e246","DOI":"10.1016\/j.jhep.2024.02.001","article-title":"Systemic metabolic abnormalities: key drivers of complications and mortality in MASLD.","volume":"80","author":"Fan","year":"2024","journal-title":"J Hepatol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"12663","DOI":"10.1038\/s41598-024-63453-6","article-title":"Impact of metabolic phenotype and alcohol consumption on mortality risk in metabolic dysfunction-associated fatty liver disease: a population-based cohort study.","volume":"14","author":"Charatcharoenwitthaya","year":"2024","journal-title":"Sci Rep"},{"key":"B24","doi-asserted-by":"publisher","first-page":"744713","DOI":"10.3389\/fmed.2021.744713","article-title":"The effects of modest alcohol consumption on non-alcoholic fatty liver disease: a systematic review and meta-analysis.","volume":"8","author":"Wongtrakul","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"B25","doi-asserted-by":"publisher","first-page":"185","DOI":"10.15288\/jsad.2016.77.185","article-title":"Do \u201cmoderate\u201d drinkers have reduced mortality risk? A systematic review and meta-analysis of alcohol consumption and all-cause mortality.","volume":"77","author":"Stockwell","year":"2016","journal-title":"J Stud Alcohol Drugs"},{"key":"B26","doi-asserted-by":"publisher","first-page":"4585","DOI":"10.1038\/s41598-021-84181-1","article-title":"Low-level alcohol consumption and cancer mortality.","volume":"11","author":"Ko","year":"2021","journal-title":"Sci Rep"},{"key":"B27","doi-asserted-by":"publisher","first-page":"219","DOI":"10.35946\/arcr.v38.2.06","article-title":"Alcohol\u2019s effects on the cardiovascular system.","volume":"38","author":"Piano","year":"2017","journal-title":"Alcohol Res"},{"key":"B28","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.atherosclerosis.2005.06.037","article-title":"Moderate alcohol consumption and lower levels of inflammatory markers in US men and women.","volume":"186","author":"Pai","year":"2006","journal-title":"Atherosclerosis"},{"key":"B29","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.jacc.2014.03.048","article-title":"Alcohol consumption and risk of atrial fibrillation: a prospective study and dose-response meta-analysis.","volume":"64","author":"Larsson","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"604919","DOI":"10.3389\/fmed.2020.604919","article-title":"Cigarette smoking increased risk of overall mortality in patients with non-alcoholic fatty liver disease: a nationwide population-based cohort study.","volume":"7","author":"Charatcharoenwitthaya","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"B31","doi-asserted-by":"publisher","first-page":"101127","DOI":"10.1016\/j.jhepr.2024.101127","article-title":"Characteristics and long-term mortality of individuals with MASLD, MetALD, and ALD, and the utility of SAFE score.","volume":"6","author":"Sripongpun","year":"2024","journal-title":"JHEP Rep"},{"key":"B32","doi-asserted-by":"publisher","first-page":"3173","DOI":"10.3390\/nu13093173","article-title":"Alcohol and cancer: epidemiology and biological mechanisms.","volume":"13","author":"Rumgay","year":"2021","journal-title":"Nutrients"},{"key":"B33","doi-asserted-by":"publisher","first-page":"3336","DOI":"10.3390\/jcm12093336","article-title":"Smoking increases the risk of hepatocellular carcinoma and cardiovascular disease in patients with metabolic-associated fatty liver disease.","volume":"12","author":"Yoo","year":"2023","journal-title":"J Clin Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1111\/liv.16091","article-title":"Socioeconomic factors associated with the presence of and outcomes in metabolic dysfunction-associated steatotic liver disease.","volume":"44","author":"Nasr","year":"2024","journal-title":"Liver Int"},{"key":"B35","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1007\/s10620-024-08722-0","article-title":"Disparities in metabolic dysfunction-associated steatotic liver disease prevalence, diagnosis, treatment, and outcomes: a narrative review.","volume":"70","author":"Miller","year":"2025","journal-title":"Dig Dis Sci"},{"key":"B36","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1097\/MEG.0000000000002497","article-title":"Validation of nonalcoholic fatty liver disease (NAFLD) related steatosis indices in metabolic associated fatty liver disease (MAFLD) and comparison of the diagnostic accuracy between NAFLD and MAFLD.","volume":"35","author":"Chen","year":"2023","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1002\/jcsm.12719","article-title":"Non-alcoholic fatty liver disease and sarcopenia additively increase mortality: a Korean nationwide survey.","volume":"12","author":"Moon","year":"2021","journal-title":"J Cachexia Sarcopenia Muscle"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1832416\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T04:35:16Z","timestamp":1782189316000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1832416\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":37,"alternative-id":["10.3389\/fmed.2026.1832416"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1832416","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"article-number":"1832416"}}